Other versions:

(Verbatim name)

ID

(Catalog Number)

ORG

DES

Invalid DOI was provided, please try again

XML
PDF
Bluesky
Twitter
Facebook
Telegram
Mendeley
Reddit
Notify a colleague
  • ContentsContents
  • Article InfoArticle Info
  • CiteCite
  • MetricsMetrics
  • CommentComment
  • RelatedRelated
  • FigsFigs
  • TabsTabs
  • RefsRefs
  • CitedCited
  • ErratumErratum
  • Article title
  • Abstract
  • Key words
  • 1.0 Introduction
  • 2.0 Pathophysiological concepts
    • 2.1 The myofibroblasts and other fibroblast subsets
    • 2.2 The early inflammatory phase
    • 2.3 The role of autoantibodies
    • 2.4 The cellular network
  • 3.0 Clinical characteristics of fibrosing skin diseases
    • 3.1 Lichen sclerosus
    • 3.2 Chronic (sclerodermiform) Graft versus Host Disease (GvHD)
    • 3.3 Scleroedema of Buschke
    • 3.4 Scleromyxoedema
    • 3.5 Localized scleroderma
    • 3.6 Systemic sclerosis (scleroderma) (SSc)
      • 3.6.1 Established therapeutic approaches for SSc in the daily practice
      • 3.6.2 Specific therapeutic challenges of skin manifestations in SSc
  • 4.0 New therapeutic options for severe fibrotic skin diseases
    • 4.1 B- and T-cell targeted approaches
    • 4.2 Modulation of macrophage activities
    • 4.3 TGF-ß related cytokines and therapeutic approaches
    • 4.4 Inhibition of signaling pathways by JAK inhibitors
    • 4.5 Other approaches to modulate inflammation and fibrosis
  • 5.0 Perspectives and future therapeutic developments
  • Additional information
    • Conflict of interest
    • Artificial Intelligence (AI) use
    • Funding
    • Author contributions
    • Author ORCIDs
    • Data availability
  • References
Subscribe to email alerts for current Article's categories
Powered by